HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Nexium 24HR Rides Blockbuster History Into Full Field Of Competitors

This article was originally published in The Tan Sheet

Executive Summary

Pfizer launches Nexium 24HR, the OTC progeny of AstraZeneca PLC’s prescription drug marketed in the U.S. as “the purple pill,” into the nonprescription PPI market, where other well-known brands and private label versions of some products already compete for share.

Advertisement

Related Content

Perrigo's Next Private Label First Lands With Second Thoughts On Outlook
Perrigo's Next Private Label First Lands With Second Thoughts On Outlook
Perrigo’s Outgoing CEO Advocates OTC Switches, Starting With Statins
Perrigo’s Outgoing CEO Advocates OTC Switches, Starting With Statins
Perrigo’s Outgoing CEO Advocates OTC Switches, Starting With Statins
Nexium OTC Switch Would Face Crowded Field, Potential Questions

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS106887

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel